Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 507789 NSE: JAGSNPHARM Pharmaceuticals & Drugs | Small Cap | Jagsonpal Pharma Share Price
₹237.05 -2.15 (-0.90%)
As on 02-Sep'26 16:59
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 507789 NSE: JAGSNPHARM Pharmaceuticals & Drugs | Small Cap | Jagsonpal Pharma Share Price
₹237.05 -2.15 (-0.90%)
As on 02-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹1,564 Cr.
Current Price
₹237.1
52-Week Low / High
₹155 / 265
TTM EPS
₹6.9
TTM Sales
₹294 Cr.
Book Value per Share
₹38
P/E Ratio
34.38
In line with its 5-year historical median
Industry PE
54.5
Price to Book (P/B)
6.24
In line with its 5-year historical median
Price to Sales (P/S)
5.32
Higher than its 5-year historical median
EV/EBITDA
19.94
Lower than its 5-year historical median
Dividend Yield
1.05%
Profitability Efficiency
Return on Equity (ROE)
18.19%
Outperforms industry median
Return on Capital Employed (ROCE)
22.69%
Outperforms industry median
Return on Assets (ROA)
14.18%
Operating Profit Margin
19%
Net Profit Margin
15%
Gross Profit Margin
22.7%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
28.76%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
13.71%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-22.18%
Asset Quality
Promoter Holding
69.05%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹238 Cr.
Equity
₹13.2 Cr.
Face Value
₹2
All Time Low / High
₹0.50 / 328.02
Check Before You Invest
Quality
Very GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Jagsonpal Pharmaceuticals Ltd a good quality company?
Jagsonpal Pharmaceuticals Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Jagsonpal Pharmaceuticals Ltd performance compare with that of its Peers?
Revenue growth of Jagsonpal Pharmaceuticals Ltd vs industry peers?
Jagsonpal Pharmaceuticals Ltd revenue CAGR is 11.13%, compared to the industry median CAGR of 5.82%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Jagsonpal Pharmaceuticals Ltd?
Promoters hold 69.05% of the Jagsonpal Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Jagsonpal Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 32.9% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Jagsonpal Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 7.3% | 14.3% | -10.5% | 9.8% | 9.5% | 19.4% | 21.2% | 24.2% | 17.7% | 33.1% | - |
| Value Creation Index ⓘ | -0.5 | 0.0 | -1.8 | -0.3 | -0.3 | 0.4 | 0.5 | 0.7 | 0.3 | 1.4 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 209 | 269 | 294 |
| Sales YoY Gr. | - | 0.3% | -12.1% | 31.9% | -5% | 18.5% | 15.8% | 8.8% | -11.8% | 28.8% | - |
| Adj EPS ⓘ | 0.5 | 0.4 | -1.8 | 1.1 | 1.2 | 2.6 | 2.8 | 4.4 | 3.4 | 6.3 | 6.9 |
| YoY Gr. | - | -12% | -500% | NA | 9.1% | 116.7% | 7.7% | 57.1% | -22.7% | 84.1% | - |
| BVPS (₹) ⓘ | 13.8 | 15.6 | 13.8 | 14.8 | 15.8 | 17.4 | 20.3 | 22.9 | 25.8 | 32.8 | 38 |
| Adj Net Profit ⓘ | 3.3 | 2.9 | -11.6 | 7.2 | 7.9 | 17.1 | 18.4 | 28.8 | 22.5 | 41.6 | 45 |
| Cash Flow from Ops. ⓘ | 9 | -3.2 | -1.6 | 30.9 | 11.9 | 28.2 | 6.9 | 46.7 | 35.2 | 55.1 | - |
| Debt/CF from Ops. ⓘ | 4.3 | -2.5 | -5.3 | 0.1 | 0.5 | 0.2 | 0 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 7.2% | 11.1% | 7.3% | 28.8% | ||||
| Adj EPS ⓘ | 32.4% | 39.2% | 30.8% | 84.1% | ||||
| BVPSⓘ | 10.1% | 15.8% | 17.4% | 27.4% | ||||
| Share Price | 32.9% | 32.5% | 11.9% | -4.6% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 3.4 | 2.8 | -11.1 | 7.1 | 7.3 | 14.6 | 14.4 | 19.7 | 13 | 19.5 | 19.5 |
| Op. Profit Mgn % ⓘ | 8.2 | 4 | -8.8 | 5.6 | 5.4 | 10.2 | 11.7 | 14.6 | 11.1 | 19 | 20.8 |
| Net Profit Mgn % ⓘ | 2.3 | 2 | -9.1 | 4.3 | 5 | 9.1 | 8.4 | 12.2 | 10.8 | 15.5 | 15.5 |
| Debt to Equity ⓘ | 0.4 | 0.1 | 0.1 | 0 | 0.1 | 0.1 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 227 | 243 | 277 | 178 | 82 | 65 | 102 | 96 | 92 | 68 | 111 |
| Cash Conv. Cycle ⓘ | 180 | 190 | 209 | 110 | 26 | 10 | 26 | 26 | 27 | 20 | 91 |
Valuation of Jagsonpal Pharma - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 209 | 269 | 287 |
| Operating Expenses ⓘ + | 138 | 138 | 157 | 150 | 169 | 193 | 203 | 186 | 218 | 229 |
| Operating Profit ⓘ | 6 | -11 | 9 | 9 | 19 | 25 | 34 | 23 | 51 | 58 |
| Operating Profit Margin (%) | 4.0% | -8.8% | 5.6% | 5.4% | 10.2% | 11.5% | 14.4% | 11.1% | 19.0% | 20.2% |
| Other Income ⓘ + | 0 | 0 | 1 | 3 | 4 | 3 | 6 | 9 | 8 | 12 |
| Interest ⓘ | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| Depreciation ⓘ | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 8 | 9 |
| Profit Before Tax ⓘ | 14 | -12 | 9 | 9 | 22 | 27 | 35 | 30 | 70 | 58 |
| Tax ⓘ | 3 | -0 | 2 | 2 | 5 | 8 | 8 | 7 | 14 | 14 |
| Profit After Tax | 12 | -12 | 7 | 8 | 17 | 19 | 27 | 22 | 55 | 43 |
| PAT Margin (%) | 8.3% | -9.1% | 4.3% | 5.0% | 9.1% | 8.7% | 11.3% | 10.8% | 20.6% | 15.0% |
| Adjusted EPS (₹) | 1.8 | -1.8 | 1.1 | 1.2 | 2.6 | 2.9 | 4.1 | 3.4 | 8.3 | 6.4 |
| Dividend Payout Ratio (%) | 2.20% | -2.30% | 9.10% | 16.60% | 15.40% | 55.60% | 49% | 58.90% | 30% | 85.50% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 110 | 98 | 104 | 111 | 122 | 133 | 150 | 170 | 218 | 256 | |
| Debt + | 8 | 8 | 4 | 6 | 7 | 0 | 0 | 0 | 0 | 0 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 9 | 9 | 12 | 12 | 18 | 19 | 17 | 8 | 10 | 12 | |
| Others Liabilities ⓘ | 16 | 14 | 16 | 20 | 17 | 20 | 36 | 47 | 51 | 62 | |
| Total Liabilities ⓘ | 143 | 130 | 136 | 149 | 164 | 171 | 203 | 225 | 278 | 329 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 22 | 21 | 22 | 24 | 26 | 23 | 24 | 9 | 94 | 85 | |
| CWIP ⓘ | 0 | 3 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Investments ⓘ | 0 | 0 | 0 | 11 | 15 | 51 | 1 | 0 | 0 | 0 | |
| Inventories | 48 | 51 | 33 | 29 | 30 | 30 | 21 | 15 | 15 | 15 | |
| Trade Receivables | 39 | 25 | 21 | 21 | 13 | 16 | 21 | 11 | 13 | 17 | |
| Cash Equivalents | 20 | 15 | 39 | 40 | 60 | 25 | 115 | 148 | 129 | 106 | |
| Others Assets ⓘ | 14 | 14 | 18 | 20 | 21 | 28 | 21 | 41 | 27 | 106 | |
| Total Assets ⓘ | 143 | 130 | 136 | 149 | 164 | 171 | 203 | 225 | 278 | 329 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | -3 | -2 | 31 | 12 | 28 | 7 | 47 | 35 | 55 | 47 |
| Cash Flow From Investing Activity ⓘ + | 41 | -3 | -1 | -11 | -2 | -26 | -58 | -25 | -45 | -36 |
| Cash Flow From Financing Activity ⓘ + | -34 | -1 | -6 | -2 | -7 | -18 | -0 | -9 | -12 | -12 |
| Net Cash Flow ⓘ | 5 | -6 | 24 | -1 | 19 | -36 | -11 | 2 | -2 | -1 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 12.32 | -12.01 | 7.72 | 7.88 | 15.7 | 15.28 | 18.89 | 14.02 | 28.51 | 18.19 |
| ROCE (%) | 14.26 | -10.52 | 9.8 | 9.46 | 19.43 | 21.23 | 24.15 | 17.72 | 33.14 | 22.69 |
| Asset Turnover Ratio | 0.96 | 0.93 | 1.26 | 2.23 | 2.4 | 1.45 | 1.38 | 1.05 | 1.12 | 1 |
| PAT to CFO Conversion(x) | -0.25 | N/A | 4.43 | 1.5 | 1.65 | 0.37 | 1.74 | 1.59 | 1 | 1.09 |
| Working Capital Days | ||||||||||
| Receivable Days | 102 | 93.10 | 50.20 | 24.30 | 16.60 | 21.30 | 25.90 | 25.90 | 15.60 | 18.20 |
| Inventory Days | 110 | 142.80 | 92 | 35.70 | 28.70 | 44.80 | 35.80 | 29 | 19.60 | 17.90 |
| Payable Days | 49.20 | 54 | 52.50 | 76.60 | 67.20 | 75.10 | 69.40 | 55.20 | 32.80 | 37.30 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Jagsonpal Pharmaceuticals Ltd FAQs
The current trading price of Jagsonpal Pharma on 02-Sep-2026 16:59 is ₹237.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Sep-2026 the market cap of Jagsonpal Pharma stood at ₹1,563.5 Cr
The latest P/E ratio of Jagsonpal Pharma as of 01-Sep-2026 is 34.38.
The latest P/B ratio of Jagsonpal Pharma as of 01-Sep-2026 is 6.24.
The 52-week high of Jagsonpal Pharma is ₹264.6 and the 52-week low is ₹154.9.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Jagsonpal Pharma is ₹294 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Jagsonpal Pharmaceuticals Ltd is a good quality company.
The key valuation ratios of Jagsonpal Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Jagsonpal Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Jagsonpal Pharmaceuticals Ltd
In 1964 Jagsonpal started from humble beginnings with Jagmohan S. Kochhar operating a chemists shop in Delhi. Soon he expanded into making formulations. Mr. Kochhar’s vision was to spread health and healing in India on a larger scale. He was at the helm of the company from its inception, through the startup phase. Even though Jagsonpal was a small business at the time, his vision was to create one of India’s premiere pharmaceutical companies.
In 1978, Fourteen years later, the company had outgrown the startup phase and was incorporated as a private limited company. Jagsonpal was now a fast growing pharmaceutical company. The firm was committed to healing India with quality pharmaceutical products and had its eyes firmly set on becoming one of the country’s leading pharmaceutical companies.
In 1986 Jagsonpal went public on the BSE. This was the first time the firm had tapped the capital markets.
In 1994 the company was listed on the NSE. This trait of not being content with the status quo has become a core part of Jagsonpal’s company culture. Commitment to growth is ingrained in the very soul of the company and this is reflected in the Jagsonpal’s current aggressive growth strategy.
Jagsonpal is among India’s premiere pharmaceutical companies. Jagsonpal has substantial research and development, manufacturing, marketing and distribution facilities. An impeccable track record of growth and profitability spanning over 4 decades, makes Jagsonpal an ideal company to partner with. The company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. The firm is committed to sustainable growth and is aggressively pursuing growth through market penetration, market expansion and multi-national expansion.
The firm’s objective is to increase market share and become a dominant player in the Indian Pharmaceutical Industry.Jagsonpal has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe making it a truly international operation.
Product range of the company includes:
- Dextropropoxyphene
- Tolnaftate
- Indocap SR
- Sterile Unipacks
- Thiopental sodium
Upcoming products:
- Nandralone laurate
- Ethisterone
- Norgestimate
- Estradiol
- Estradiol benzoate
- Estradiol valerate
- Estradiol phenylpropionate
- Mifepristone
- Finasteride/dutasteride
- Budesonide
- Cyproterone/acetate
- Mestranol
- Llynestrenol
- Norethisterone enanthate
- Estriol base and succinate
- Ethinyl estradiol
- Estrone
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
